Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries OraSure to Participate in Upcoming Investor Conferences By: OraSure Technologies, Inc. via GlobeNewswire November 13, 2023 at 16:15 PM EST BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ETEvercore ISI Annual HealthCONx Conference on Tuesday, November 28, with a Q&A session scheduled for 3 p.m. ET Live webcasts and replays of the sessions will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcasts will be archived on OraSure’s website and will be available for approximately 90 days. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information through effortless tests, collection kits, and services. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com. Investor Contact:Media Contact:Jason PlagmanAmy KochVP, Investor RelationsDirector, Corporate Communicationsinvestorinfo@orasure.commedia@orasure.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
OraSure to Participate in Upcoming Investor Conferences By: OraSure Technologies, Inc. via GlobeNewswire November 13, 2023 at 16:15 PM EST BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ETEvercore ISI Annual HealthCONx Conference on Tuesday, November 28, with a Q&A session scheduled for 3 p.m. ET Live webcasts and replays of the sessions will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcasts will be archived on OraSure’s website and will be available for approximately 90 days. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information through effortless tests, collection kits, and services. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com. Investor Contact:Media Contact:Jason PlagmanAmy KochVP, Investor RelationsDirector, Corporate Communicationsinvestorinfo@orasure.commedia@orasure.com
BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ETEvercore ISI Annual HealthCONx Conference on Tuesday, November 28, with a Q&A session scheduled for 3 p.m. ET Live webcasts and replays of the sessions will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcasts will be archived on OraSure’s website and will be available for approximately 90 days. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information through effortless tests, collection kits, and services. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com. Investor Contact:Media Contact:Jason PlagmanAmy KochVP, Investor RelationsDirector, Corporate Communicationsinvestorinfo@orasure.commedia@orasure.com